Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
Recruiting
N/A
Interventional Study
Hepatocellular Carcinoma
Radiation Exposure
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Health Services Research
- Participants needed
- 20 (estimated)
- Sponsor
- University of Tennessee · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study
* Must be able to schedule and tolerate additional PET/CT imaging following therapy
* Must be able to tolerate additional blood draws before, during…
Contacts